On September 24th global experts on malignant pleural mesothelioma will convene for the 6th Annual International Symposium on Malignant Pleural Mesothelioma.

LOS ANGELES, CALIFORNIA, U.S., August 30, 2016 /EINPresswire.com/ -- On September 24th global experts on malignant pleural mesothelioma will convene at the new Meyer & Renee Luskin Conference Center at UCLA for the 6th Annual International Symposium on Malignant Pleural Mesothelioma (MPM), a rare form of cancer that results from exposure to asbestos and commonly affects the lining of the chest– the pleura. The event is jointly hosted by UCLA and the Pacific Mesothelioma Center (PMC).
The Symposium is geared towards physicians and offers continuing medical education (CME) credit. It will also provide up-to-date information on mesothelioma for medical students, nurses and other healthcare professionals, as well as mesothelioma patients, their families and other interested parties. Topics will cover: options for intraoperative adjuvant therapies, updates from recent mesothelioma clinical trials, cryoablation in management of recurrent mesothelioma, the role of immunotherapy in advanced pleural mesothelioma, genetic immunotherapy for malignant pleural mesothelioma and more.
The Symposium will be led by Robert B. Cameron, MD, FACS, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center. The roster of distinguished international faculty at the Symposium will include Edgar G. Engleman, MD of Stanford University, Thierry M. Jahan, MD of UCSF, Edmund K. Moon, MD of the University of Pennsylvania, Richard Morgan, PhD of the University of Bradford, Daniel H. Sterman, MD of NYU, and Haining Yang, MD, PhD, of the University of Hawaii as well as local experts from UCLA.
“This event highlights medical advances in the treatment of mesothelioma and promising areas of new research,” said Dr. Cameron. “One of the most exciting areas of research is immunotherapy, and our panel of experts will discuss genetic immunotherapy, dendritic cells, adoptive therapy with chimeric antigen receptor T cells, as well as a novel gene-modified stem cell immunotherapy. We even will have a discussion about the real possibility of the early detection and prevention of mesothelioma.”
The Symposium is supported by: Worthington & Caron, P.C., Eli Lily & Company and the International Association of Heat & Frost Insulators.
Early Bird tickets can be purchased before September 9th online at http://www.cme.ucla.edu/courses/.
About The Pacific Mesothelioma Center:
The Pacific Heart, Lung & Blood Institute (PHLBI) is a 501(c)(3) non-profit medical research institute established in 2002. One of the divisions, The Pacific Mesothelioma Center (PMC) is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC’s unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options. PMC also connects newly diagnosed patients with patients that have been through treatment and provides assistance and emotional support.

Clare Cameron
The Pacific Mesothelioma Center
310-478-4678
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.